Literature DB >> 15149585

Treatment of Clostridium difficile Infection.

John R. Stroehlein1.   

Abstract

With the introduction of broad-spectrum antibiotics into clinical practice, Clostridium difficile infection has become the most common cause of infectious diarrhea in hospitalized patients. Although mild cases may resolve by discontinuing antibiotics, thus allowing re-establishment of colonic microflora, oral metronidazole or vancomycin is indicated if the process is more severe. Metronidazole may be given intravenously, with intracolonic therapeutic levels achieved by excretion of drug into bile and exudation across inflamed tissue. Vancomycin is preferred treatment of severe cases. Bacitracin given orally is a therapeutic alternative and cholestyramine is a useful adjunct. Most patients with diarrhea or colitis caused by C. difficile respond to initial therapy; however, up to 20% experience relapse when treatment is discontinued. Repeating initial therapy for 10 to 14 days is indicated for first relapse. Multiple relapses require prolonged treatment with vancomycin, which may be supplemented with cholestyramine. Saccharomyces boulardii alone or in combination with vancomycin has been reported to be an effective therapeutic alternative for recurrent infection. Intravenous immunoglobulin can be effective in patients with severe recurrent Clostridium difficile colitis and immune deficiency or low pretreatment levels of serum antitoxin. Surgery is indicated only if recurrent infections are severe and associated with serious complications.

Entities:  

Year:  2004        PMID: 15149585     DOI: 10.1007/s11938-004-0044-y

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  27 in total

1.  Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.

Authors:  R Fekety; J Silva; C Kauffman; B Buggy; H G Deery
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

Review 2.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

3.  Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.

Authors:  C M Surawicz; L V McFarland; G Elmer; J Chinn
Journal:  Am J Gastroenterol       Date:  1989-10       Impact factor: 10.864

4.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

5.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors:  J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

6.  Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum.

Authors:  C Pothoulakis; C P Kelly; M A Joshi; N Gao; C J O'Keane; I Castagliuolo; J T Lamont
Journal:  Gastroenterology       Date:  1993-04       Impact factor: 22.682

7.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

8.  Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces.

Authors:  A Schwan; S Sjölin; U Trottestam; B Aronsson
Journal:  Scand J Infect Dis       Date:  1984

9.  Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.

Authors:  M B Kimmey; G W Elmer; C M Surawicz; L V McFarland
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

10.  Colitis associated with metronidazole therapy.

Authors:  R Saginur; C R Hawley; J G Bartlett
Journal:  J Infect Dis       Date:  1980-06       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.